Christopher King, MD
Interventional Cardiology · Birmingham, ALNPI 1629191168
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,672 and has fallen 76.0% since, to $641 in 2025.
Across 363 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$2K
- Angiodynamics, Inc.$1K
- Novartis$1K
- Medtronic$390
- Amgen$368
- Silk Road Medical, Inc.$350
- plus $4K from 41 others
Across 32 payments — averaging $1048.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$34K
What the payments were for
- Consulting fees$3504%
- Travel & lodging$4745%
- Food & beverage$8,22091%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$893
- FLOWTRIEVER CATHETER, S$889
- CT THROMBECTOMY SYSTEM KIT$889
- ENROUTE Transcarotid Neuroprotection System$700
- FlowTriever$430
- ClotTriever$430
- ENROUTE Transcarotid Stent$350
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$350
- OPTIMIZER$276
- Abre$160
- HawkOne$117
- Impella$100
How this compares
$9,056 in reported general payments places this provider in the 65th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 334 | $308,383 |
| EntrestoSacubitril/Valsartan | 98 | $80,150 |
| XareltoRivaroxaban | 60 | $65,166 |
| Repatha SureclickEvolocumab | 59 | $42,222 |
| JardianceEmpagliflozin | 31 | $31,049 |
| MultaqDronedarone Hcl | 17 | $19,717 |
| BrilintaTicagrelor | 13 | $9,799 |
| Metoprolol Succinate | 353 | $6,135 |
| Ranolazine ErRanolazine | 44 | $4,030 |
| Atorvastatin Calcium | 279 | $3,448 |
| Flecainide Acetate | 37 | $2,557 |
| ClopidogrelClopidogrel Bisulfate | 270 | $2,550 |
| Prasugrel Hcl | 18 | $2,545 |
| Potassium Chloride | 161 | $2,297 |
| Rosuvastatin Calcium | 73 | $1,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $276 | $308,383334 claims |
| NovartisEntresto | $1,018 | $80,15098 claims |
| Johnson & JohnsonXarelto | $342 | $65,16660 claims |
| Boehringer IngelheimJardiance | $265 | $31,04931 claims |
| Sanofi-aventis U.S. LLCMultaq | $273 | $19,71717 claims |
| AstraZenecaBrilinta | $135 | $9,79913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Birmingham
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
- Jacob TownsendBirmingham$52K
- Kamran AliBirmingham$47K
- Mouhamed SabouniBirmingham$44K
- David SchultzBirmingham$19K
- Tushar MishraBirmingham$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.